2024年美國臨床腫瘤學會年會(American Society of Clinical Oncology,ASCO)將于5月31日至6月4日在美國芝加哥舉行,榮昌生物(股票代碼:688331.SH / 09995.HK)將攜重磅研究成果再次登上這一頂尖國際學術舞臺,唱響中國創新藥好聲音,展示開創性新治療手段的“中國方案”。

在本次大會上,榮昌生物原創原研的我國首個獲批上市的國產抗體偶聯(ADC)藥物維迪西妥單抗、靶向間皮素(MSLN)ADC藥物RC88等兩款創新藥的16項最新臨床研究數據,將精彩亮相,具體包括1項臨床科學研討、5項壁報展示、10項線上摘要,覆蓋胃癌、膀胱癌、婦瘤等多個癌種,不僅有單藥還有多種聯合療法。讓我們搶先看看榮昌生物入選本屆ASCO大會的“豪華陣容”!


1項臨床科學研討

維迪西妥單抗(RC48)聯合替雷利珠單抗和S-1治療一線HER2過表達晚期胃或胃食管結合部腺癌的療效:一項多中心、單組、II期試驗(RCTS)

Efficacy of disitamab vedotin (RC48) plus tislelizumab and S-1 as first-line therapy for HER2-overexpressing advanced stomach or gastroesophageal junction adenocarcinoma: A multicenter, single-arm, phase II trial (RCTS).

摘要編號:#4009

展示形式:臨床科學研討會

展示時間:6月2日下午4:30(美國東部時間)

第一作者:劉聯教授 山東大學齊魯醫院 

5項壁報展示

01

RC88在卵巢癌、非鱗狀非小細胞肺癌和宮頸癌患者中的療效和安全性:一項首次人體1/2期臨床研究的結果

The efficacy and safety of RC88 in patients with ovarian cancer, non-squamous-non-small-cell lung-carcinoma and cervical cancer: Results from a first-in-human phase 1/2 study.

摘要編號:#5551 

壁報編號:#422 

展示形式:壁報展示

展示時間:6月3日上午9:00(美國東部時間)

第一作者:劉雨桃教授 中國醫學科學院腫瘤醫院

02

RC48-C017的初步療效和安全性結果:一項針對HER2表達的肌層浸潤性膀胱癌(MIBC)患者使用維迪西妥單抗聯合特瑞普利單抗進行新輔助治療的II期研究

Preliminary efficacy and safety results from RC48-C017: A phase II study of neoadjuvant treatment with disitamab vedotin plus toripalimab in patients with muscle invasive bladder cancer (MIBC) with HER2 expression.

摘要編號:#4568

壁報編號:#263 

展示形式:壁報展示

展示時間:6月2日上午9:00(美國東部時間)

第一作者:盛錫楠教授 北京大學腫瘤醫院

03

維迪西妥單抗(RC48-ADC)治療HER2過表達的高危非肌層浸潤性膀胱癌:一項II期多中心研究

Adjuvant or rescue disitamab vedotin (RC48-ADC) for high-risk non-muscle invasive bladder cancer with HER2 overexpression: A phase II multi-center study.

摘要編號:#TPS4625

壁報編號:#311a

展示形式:壁報展示

展示時間:6月2日上午9:00(美國東部時間)

主要研究者:曾浩教授 四川大學華西醫院

第一作者:陳俊儒教授 四川大學華西醫院

04

評價維迪西妥單抗治療HER2表達的2L復發或轉移性宮頸癌(r/mCC)有效性和安全性:RC48-C018的中期結果

Evaluation of the effectiveness and safety of disitamab vedotin in HER2-expressing 2L recurrent or metastatic cervical cancer (r/mCC): Interim results of RC48-C018.

摘要編號:#5528

壁報編號:#399 

展示形式:壁報展示

展示時間:6月3日上午9:00(美國東部時間)

第一作者:袁光文教授 中國醫學科學院腫瘤醫院

05

一項前瞻性、單臂、單中心臨床研究:維迪西妥單抗聯合特瑞普利單抗治療進展或對順鉑化療不耐受的晚期陰莖癌患者

SAVE: A prospective, single-arm, single-center clinical study of disitamab vedotin in combination with toripalimab in patients with advanced penile cancer that has progressed or is intolerant to cisplatin chemotherapy.

摘要編號:#TPS5107

壁報編號:#513a

展示形式:壁報展示

展示時間:6月2日上午9:00(美國東部時間)

第一作者:袁方教授  重慶大學附屬腫瘤醫院

10項線上摘要

01

#e13011評價維迪西妥單抗在HER-2表達的乳腺癌中的療效與安全性:一項多中心回顧性研究

Efficacy and safety of disitamab vedotin (RC48) in HER2-expressing breast cancer: A multicenter retrospective study

02

#e13022維迪西妥單抗(RC48)治療HER2陽性晚期乳腺癌的有效性和安全性:來自中國的真實世界經驗

Effectiveness and safety of disitamab vedotin (RC48) in pretreated HER2-positive advanced breast cancer: A real-world experience in China.

03

#e12636重組人源化抗HER2抗體-MMAE結合物(RC48)用于HER2陽性乳腺癌新輔助治療的有效性和安全性:一項單臂II期研究

Efficacy and safety of recombinant humanized anti-HER2 antibody-MMAE conjugate (RC48) in neoadjuvant for HER2-positive breast cancer: A single-arm phase II study.

04

#e15003維迪西妥單抗聯合呋喹替尼治療至少兩種標準療法難治的HER2表達或HER2突變/擴增的轉移性結直腸癌患者:一項前瞻性、探索性、單臂研究

Disitamab vedotin combined with fruquintinib in patients with HER2-expressing or HER2 mutation/amplified metastatic colorectal cancer refractory to at least two standard regimens: A prospective, exploratory, single-arm study.

05

#e16590維迪西妥單抗聯合特瑞普利單抗新輔助治療肌層浸潤性膀胱癌后選擇性保膀胱或根治性膀胱切除術的有效性和安全性

Efficacy and safety of neoadjuvant therapy with disitamab vedotin plus toripalimab in treating muscle invasive urothelial bladder cancer followed by selective bladder-preserving or radical cystectomy.

06

#e16614 HER2過表達的膀胱癌(BC)的腫瘤免疫特征,以及對HER2過度表達的高風險非肌層浸潤性BC的RC48-ADC對比卡介苗的研究

The tumor immune profile of bladder cancer (BC) with HER2 over-expression and the investigation into RC48-ADC versus BCG in high-risk non-muscle invasive BC with HER2 over-expression.

07

#e16595 RC48-ADC聯合替雷利珠單抗作為HER2陽性局部晚期肌層浸潤性尿路上皮膀胱癌患者新輔助治療的多中心Ib/II期研究(Hope-03)初步結果

Preliminary results from a multi-center phase Ib/II study of RC48-ADC combined with tislelizumab as neoadjuvant treatment in patients with HER2 positive locally advanced muscle-invasive urothelial bladder cancer (Hope-03).

08

#e16100維迪西妥單抗(RC48)聯合卡瑞利珠單抗和S-1用于HER2過表達的局部晚期胃癌新輔助治療的有效性和安全性:一項前瞻性單臂II期研究的初步結果

Efficacy and safety of disitamab vedotin (RC48) combined with camrelizumab and S-1 for neoadjuvant therapy of locally advanced gastric cancer with HER2 overexpression: Preliminary results of a prospective, single-arm, phase II study.

09

#e16572維迪西妥單抗(DV,RC48-ADC)聯合卡度尼利單抗(抗PD-1/CTLA-4雙特異性抗體)治療局部晚期或轉移性尿路上皮癌(la/mUC)患者:一項開放標簽、單臂II期研究

Disitamab vedotin (DV, RC48-ADC) combined with cadonilimab (anti-PD-1/CTLA-4 bispecific antibody) in patients with locally advanced or metastatic urothelial carcinoma (la/mUC): An open-label, single-arm, phase II study.

10

#e16591一項評估圍手術期維迪西妥單抗(RC48-ADC)聯合卡度尼利單抗(AK104,PD-1/CTLA-4雙特異性抗體)治療HER2表達的肌層浸潤性膀胱癌(MIBC)的療效和安全性II期研究初步結果

Preliminary results from a phase II study to evaluate the efficacy and safety of perioperative disitamab vedotin (RC48-ADC) plus cadonilimab (AK104, PD-1/CTLA-4 bispecific antibody) for HER2-expressing muscle-invasive bladder cancer (MIBC).